Andersen Nynne Nyboe, Jess Tine
Nynne Nyboe Andersen, Tine Jess, Department of Epidemiology Research, Statens Serum Institut, DK-2300 Copenhagen, Denmark.
World J Gastroenterol. 2014 Nov 21;20(43):16014-9. doi: 10.3748/wjg.v20.i43.16014.
Tumor necrosis factor-α (TNF-α) inhibitors are biological agents introduced in the late 1990s for the treatment of different immune-mediated diseases as inflammatory bowel disease, rheumatoid arthritis and psoriasis. The most commonly used TNF-α antagonists are infliximab, adalimumab, and certolizumab pegol, and though highly effective in lowering inflammation, the efficacy must be weighed against the potential for adverse events. The treatment-induced immunosuppression is suspected to increase the risk of infections, including the risk of reactivation of latent tuberculosis, as the TNF-α cytokine plays an important role in the immune function. In this topic highlight a short overview of the infection risk associated with TNF-α inhibiter therapy is outlined with a focus on the overall risk of serious infections, mycobacterial infection and latent viral infections.
肿瘤坏死因子-α（TNF-α）抑制剂是20世纪90年代末推出的生物制剂，用于治疗不同的免疫介导疾病，如炎症性肠病、类风湿性关节炎和银屑病。最常用的TNF-α拮抗剂是英夫利昔单抗、阿达木单抗和聚乙二醇化赛妥珠单抗，尽管它们在减轻炎症方面非常有效，但必须权衡其疗效与不良事件发生的可能性。由于TNF-α细胞因子在免疫功能中起重要作用，治疗引起的免疫抑制被怀疑会增加感染风险，包括潜伏性结核再激活的风险。在本主题中，重点概述了与TNF-α抑制剂治疗相关的感染风险，特别关注严重感染、分枝杆菌感染和潜伏病毒感染的总体风险。
